Dark

Check out our Level2View

DSNKY
DAIICHI SANKYO S/ADR
stock OTC ADR

EOD

Aug 6, 2026

16.88USD+2.990%(+0.49)171,243

Pre-market

0.00USD-100.000%(-16.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Sep 17, 2021

01:03PM EDT AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer Benzinga

Aug 9, 2021

04:06PM EDT AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer Benzinga

Jul 8, 2021

01:26PM EDT Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu Benzinga

Jun 15, 2021

06:07AM EDT Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan Benzinga

May 26, 2021

06:57AM EDT Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters Benzinga

May 10, 2021

06:48AM EDT AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer Benzinga

Apr 27, 2021

09:51AM EDT LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates Benzinga

Mar 31, 2021

02:26PM EDT Daiichi Axes Sanofi Vaccine Pact After Pertussis Jab Manufacturing Faces Snag Benzinga

Mar 22, 2021

01:12PM EDT Daiichi Takes mRNA COVID-19 Vaccine Into Human Trials Benzinga

Oct 28, 2020

04:57AM EDT AstraZeneca Announced Enhertu Granted FDA Priority Review in the US for the Treatment of HER2-positive Metastatic Gastric Cancer Benzinga

Jul 31, 2020

04:15AM EDT Earnings Scheduled For July 31, 2020 Benzinga

Jul 30, 2020

05:55AM EDT AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio Benzinga

Jul 27, 2020

06:43AM EDT AstraZeneca To Pay $6B To Japan's Daiichi As Part of Collaboration On New Cancer Drug Benzinga

Share